Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression PARP inhibitor therapy

U Matulonis, P Harter, Charles Gourley, M Friedlander, I Vergote, G Rustin, C Scott, W Meier, R Shapria-Frommer, T Safra, D Matei, A Fielding, S Spencer, D Parry, L Grinsted, JA Ledermann

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Publication statusPublished - 8 Apr 2016

Cite this